Trials / NCT07063030
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
Recruiting now Early Phase 1 Gene therapy
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Treatment
- LX107 Injection
- Gene
- AIPL1
- Conditions
- Retinal Dystrophy
- Ages
- 4 Years to no upper limit
- Enrollment
- 13 participants
- Started
- 2025-07-15
- Main results expected
- 2026-12-31
- Results posted
- Not yet
- Record last updated
- 2026-03-10
What the study is testing
Administering subretinal injection of LX107 injection (a gene therapy drug) to patients with retinal dystrophy caused by AIPL1 gene mutation to evaluate its efficacy and safety.
Where it runs
China (1)
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (recruiting now)